Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Jump to: 2020 | 2018
Number of items: 3.

2020

Lin, C. C., Joerger, M., Grell, P., Chiappori, A. A., Leal, T. A., Kasper, S., Jerusalem, G., Goncalves, A., Wolf, J., De Braud, F., de Jonge, M. J. A., Otero, J., Chhagan, S., Cipolletta, D., Morris, E., Chowdhury, N. R., Hurtado, F. K. and Tan, D. S. (2020). Continuous vs intermittent adenosine 2A receptor (A2AR) inhibition in preclinical colon cancer (CC) models and in a Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients ( pts) with non-small cell lung cancer (NSCLC). Eur. J. Cancer, 138. S. S12 - 2. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

2018

Tan, D. S., Kim, S-W., Sequist, L. V., Ponce Aix, S., Smit, E. F., Hida, T., Yang, J. C-H., Felip, E., Seto, T., Grohe, C., Wolf, J., Ko, J., Marriere, E., Belli, R., Giovannini, M. and Kim, D-W. (2018). Phase II results for single-agent nazartinib (EGF816) in adult patients (pts) with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC). Ann. Oncol., 29. S. 748 - 749. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Wolf, J., Seto, T., Han, J-Y., Reguart, N., Garon, E. B., Groen, H. J. M., Tan, D. S., Hida, T., de Jonge, M. J. A., Orlov, S. V., Smit, E. F., Souquet, P-J., Vansteenkiste, J. F., Giovannini, M., Le Mouhaer, S., Robeva, A., Waldron-Lynch, M. and Heist, R. S. (2018). Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with MET Delta ex14 mutated advanced non-small cell lung cancer (NSCLC). Ann. Oncol., 29. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

This list was generated on Sun Jun 26 06:10:32 2022 CEST.